Skip to main content

Table 3 Sensitivity and specificity of measurements of fractionated plasma metanephrines

From: A systematic review of the literature examining the diagnostic efficacy of measurement of fractionated plasma free metanephrines in the biochemical diagnosis of pheochromocytoma

  Sensitivity (95% CI)* Specificity (95% CI)* Likelihood ratio of a positive test* (95% CI)* Likelihood ratio of a negative test* (95% CI)*
ALL PATIENTS     
Mayo Clinic† 96% (54/56) (88%, 99%) 85% (377/445) (81%, 88%) 6.31 (5.04, 7.90) 0.02 (0.00, 0.15)
NIH 99% (211/214) (96%, 100%) 89% (575/644) (87%, 91%) 9.20 (7.36, 11.51) 0.02 (0.01, 0.05)
Vienna 100% (17/17) (82%, 100%) 100% (14/14) (78%, 100%) 29.17 (1.91, 445.60) 0.03 (0.00, 0.44)
SPORADIC PATIENTS     
Mayo Clinic 97% (38/39) (87%, 100%) 84% (335/399) (80%, 87%) 6.07 (4.83, 7.65) 0.03 (0.00, 0.21)
NIH 99% (137/138) (99%, 100%) 82% (249/305) (77%, 86%) 5.41 (4.27, 6.85) 0.01 (0.00, 0.06)
Vienna 100% (14/14) (79%, 100%) 100% (14/14) (79%, 100%) 29.00 (1.90, 443.27) 0.03 (0.00, 0.53)
  1. *Calculated † 6 subjects without pheochromocytoma who had "interfering substances" noted upon measurement of the metanephrine fraction were excluded.